PMC:7696151 / 111297-111759 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"4067","span":{"begin":71,"end":79},"obj":"Species"},{"id":"4068","span":{"begin":255,"end":263},"obj":"Species"},{"id":"4069","span":{"begin":362,"end":370},"obj":"Species"}],"attributes":[{"id":"A4067","pred":"tao:has_database_id","subj":"4067","obj":"Tax:9606"},{"id":"A4068","pred":"tao:has_database_id","subj":"4068","obj":"Tax:9606"},{"id":"A4069","pred":"tao:has_database_id","subj":"4069","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Gautret et al. (2020) [32] Open-label non-randomized clinical trial36 patients HCQ group -\u003e 600 mg/day HCQ (n = 14); 600 mg/day HCQ +500 mg AZM on day 1 followed by 250 mg/day for 4 days (n = 6)Control group (n = 16)Day 10 On day 6, 70% of HCQ-treated patients were virologically cured comparing to 12.5% in the control groupOn day 6, 100% of HCQ+AZM treated patients are virologically cured comparing to 57.1% in the HCQ group and 12.5% in the control group."}

{"project":"LitCovid-sentences","denotations":[{"id":"T756","span":{"begin":0,"end":462},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Gautret et al. (2020) [32] Open-label non-randomized clinical trial36 patients HCQ group -\u003e 600 mg/day HCQ (n = 14); 600 mg/day HCQ +500 mg AZM on day 1 followed by 250 mg/day for 4 days (n = 6)Control group (n = 16)Day 10 On day 6, 70% of HCQ-treated patients were virologically cured comparing to 12.5% in the control groupOn day 6, 100% of HCQ+AZM treated patients are virologically cured comparing to 57.1% in the HCQ group and 12.5% in the control group."}